Local field study on the effectiveness and safety of milbemycin oxime and lotilaner (Credelio® Plus) against canine gastrointestinal nematodes in the Republic of Korea

This field study evaluated the effectiveness and safety of a single dose of a combination of milbemycin oxime and lotilaner (Credelio^® Plus) against Toxocara canis, Trichuris vulpis, and Ancylostoma caninum in dogs under field conditions in Korea. This clinical study was conducted with client-owned dogs under field conditions from April 2023 to May 2024. The drug was administered on Day 0, and fecal samples were collected on Days - 7, 0, 7, and 14. Samples were analyzed using fecal flotation for qualitative assessment and the modified McMaster method for quantitative determination of egg counts. A total of 25 dogs from 25 different households were enrolled. The geometric mean reduction rates for all target nematode species and total infections were 100%. No adverse events or significant changes in body weight, physical examination findings, or hematology and serum chemistry parameters were observed. The results of this study support the effectiveness and safety of the drug against gastrointestinal nematodes in dogs under field conditions in Korea. These results indicate that this combination product may serve as a valuable tool in veterinary parasite control, ultimately contributing to improved canine health.